When the standard statistical framework says "not significant," a different analytical lens can reveal a more nuanced and potentially clinically important signal — and that distinction may matter enormously in trauma bays where decisions about blood products are made in minutes. A phase II multicenter randomized trial enrolling 200 severely injured adults at risk of hemorrhagic shock compared early cold stored platelet (CSP) transfusion against standard care across five U.S. Level 1 trauma centers between 2022 and 2023. The original frequentist analysis returned a p-value of 0.28 for 24-hour mortality — 5.9% in the CSP group versus 10.2% in standard care — technically a non-significant result that could easily be filed away as inconclusive.
A subsequent Bayesian logistic regression using an uninformative prior reframed those numbers substantially. The model calculated an 89.1% posterior probability that CSP transfusion reduced 24-hour mortality, with a posterior odds ratio indicating the treatment is 8.1 times more likely to be beneficial than harmful. Sensitivity analyses across varied prior assumptions consistently returned posterior probabilities above 81%, and a secondary beta-binomial model corroborated the directional finding at 86.2% probability of benefit.
This reanalysis exemplifies a broader methodological tension in clinical research: frequentist p-values are binary gatekeepers that can obscure clinically meaningful effect sizes, particularly in underpowered phase II trials. Cold stored platelets differ from room-temperature-stored platelets in that refrigeration preserves hemostatic activity while reducing bacterial contamination risk — a biologically plausible reason to expect superior performance in acute hemorrhage. The ~4-percentage-point absolute mortality difference observed here would be clinically substantial if confirmed in a larger phase III trial, potentially preventing tens of thousands of trauma deaths annually given hemorrhagic shock incidence. Key limitations remain: the 200-patient sample is modest, the study was not powered to detect mortality differences as a primary endpoint, and Bayesian reanalyses of existing trials carry inherent post-hoc interpretive risks. This finding is best characterized as hypothesis-strengthening rather than practice-changing — but it provides a compelling quantitative rationale for a definitive trial.